Manifold Fuels Life Sciences AI with $18 Million Series B
December 25, 2025, 9:37 am
Location: United States, California, San Francisco
Employees: 11-50
Founded date: 2000
Manifold raised $18 million in Series B funding, bringing its total to $40 million, to bolster its vertical AI platform for life sciences. Reach Capital led the round, backing Manifold's specialized "Agent OS" and secure, collaborative data ecosystem. The platform critically enhances drug discovery, streamlines clinical trials, and advances precision medicine by expertly handling complex, multimodal biomedical data. Manifold’s technology accelerates target identification, refines patient cohort selection, and tailors treatments. Partnering with institutions like Foundation Medicine and Broad Institute, Manifold significantly boosts research productivity. It speeds vital, life-changing medicines to patients. This investment cements Manifold’s role as a leader, driving the future of healthcare innovation and biomedical progress.
Manifold secured a significant $18 million. This Series B round fuels its specialized AI platform. The focus remains squarely on life sciences. Total capital raised now stands at $40 million. This marks a substantial investment in vertical AI technology. Reach Capital led the funding round. SilverArc Capital and Industry Ventures joined as participants. Existing investors TQ Ventures and Calibrate Ventures also contributed. This capital injection underscores strong market confidence. It validates Manifold’s innovative approach to healthcare technology.
Life sciences present unique AI challenges. Biomedical data is vast and highly complex. It spans genomics, proteomics, imaging, and extensive clinical records. Traditional, generalized AI often falters in this domain. Manifold offers a purpose-built solution. Its vertical AI platform navigates this inherent complexity. It expertly supports multimodal data streams. It enables seamless multi-entity collaboration across organizations. Strict governance requirements are met. This safeguards sensitive datasets crucial for research. The platform effectively streamlines workflows. It covers the entire spectrum from early discovery to clinical development and precision patient care.
Manifold's core innovation is its "Agent OS." This system significantly enhances the capabilities of AI agents. These agents operate directly on intricate biomedical data. They leverage a comprehensive suite of scientific tools. Institutional context is seamlessly integrated into their operations. This dramatically boosts research efficiency and accuracy. Use cases span critical areas in medical science. Biomarker development gains unprecedented precision. Model validation processes become more robust and reliable. Clinical trial design improves with data-driven insights. Real-world evidence generation strengthens, providing crucial feedback. The Agent OS accelerates the pace of scientific discovery.
The $18 million in new capital accelerates Manifold's strategic objectives. A primary focus is expanding the "Agent OS." This will unlock more advanced AI capabilities. It enables deeper platform integration across various scientific disciplines. Collaboration infrastructure will also deepen significantly. Research teams will share analyses more effectively. Context reuse will become frictionless across projects. Data sovereignty remains paramount throughout. The entire data ecosystem will scale. Dataset creation simplifies greatly for all users. Organizations participate without relinquishing their data ownership. This fosters a powerful, secure collaborative environment for breakthrough science.
Drug discovery is a lengthy, resource-intensive marathon. Target identification often proves slow and arduous. Manifold's AI dramatically streamlines this process. It rapidly sifts through immense, complex datasets. Promising therapeutic targets emerge faster than ever before. This accelerates preclinical research significantly. Clinical development phases also benefit from these advancements. Manifold's sophisticated tools optimize trial design. They improve patient cohort identification with greater precision. This reduces trial duration and associated costs. Life-changing medicines reach patients much sooner.
Precision medicine demands highly tailored approaches. Manifold enables truly personalized treatments. Its platform analyzes individual patient profiles with advanced algorithms. It recommends specific therapeutic pathways based on unique biological markers. Biomarker insights guide critical treatment decisions. This maximizes treatment efficacy for each patient. It simultaneously minimizes potential adverse effects. Manifold is a vital engine for achieving better patient outcomes. It bridges the critical gap between cutting-edge research and individualized clinical care.
Manifold demonstrates strong product-market fit. Its growth reflects powerful, compounding network effects. Specialized AI agents serve diverse scientific workflows. These include precise cohort identification and accurate biomarker discovery. Treatment pathway analysis improves with data-driven insights. Outcomes research gains much-needed clarity. The customer base expands rapidly, a testament to its value. Foundation Medicine utilizes the platform extensively. The University of Virginia leverages its advanced capabilities for research. Strategic partnerships further extend its reach and impact. The Broad Institute, AWS, and Anthropic are key collaborators. Manifold also operates Terra. Terra supports thousands of researchers. Hundreds of global life sciences organizations rely on its robust infrastructure.
Data silos historically impede scientific progress. Research often suffers from fragmented information sources. Manifold tackles this directly and effectively. It creates a unified data environment for diverse information. Secure sharing protocols are deeply embedded within the platform. Multi-entity collaboration flourishes within this secure ecosystem. Yet, robust data governance ensures absolute control for all participants. Researchers access vast amounts of information. They collaborate without compromising data integrity or ownership. This shared, secure infrastructure accelerates innovation across the board.
This funding signifies more than just company growth. It represents a vital investment in global scientific advancement. It pushes the boundaries of biomedical science forward. It promises significant economic gains for the entire sector. Research productivity will soar to new heights. Drug development becomes more cost-effective and efficient. Breakthroughs will accelerate across the pharmaceutical industry. Manifold stands at the forefront of this transformation. Its technology actively shapes the future. It drives the next era of groundbreaking healthcare innovation.
Manifold continues its expansion trajectory. Its technology closes critical gaps in scientific workflows. It empowers scientists and researchers globally. Future therapeutic advancements depend on such powerful tools. The platform evolves constantly. It adapts to emerging scientific needs and challenges. This ensures its lasting relevance and impact. Manifold's vision actively reshapes healthcare delivery. It builds a healthier tomorrow for countless individuals.
Manifold secured a significant $18 million. This Series B round fuels its specialized AI platform. The focus remains squarely on life sciences. Total capital raised now stands at $40 million. This marks a substantial investment in vertical AI technology. Reach Capital led the funding round. SilverArc Capital and Industry Ventures joined as participants. Existing investors TQ Ventures and Calibrate Ventures also contributed. This capital injection underscores strong market confidence. It validates Manifold’s innovative approach to healthcare technology.
Life sciences present unique AI challenges. Biomedical data is vast and highly complex. It spans genomics, proteomics, imaging, and extensive clinical records. Traditional, generalized AI often falters in this domain. Manifold offers a purpose-built solution. Its vertical AI platform navigates this inherent complexity. It expertly supports multimodal data streams. It enables seamless multi-entity collaboration across organizations. Strict governance requirements are met. This safeguards sensitive datasets crucial for research. The platform effectively streamlines workflows. It covers the entire spectrum from early discovery to clinical development and precision patient care.
Manifold's core innovation is its "Agent OS." This system significantly enhances the capabilities of AI agents. These agents operate directly on intricate biomedical data. They leverage a comprehensive suite of scientific tools. Institutional context is seamlessly integrated into their operations. This dramatically boosts research efficiency and accuracy. Use cases span critical areas in medical science. Biomarker development gains unprecedented precision. Model validation processes become more robust and reliable. Clinical trial design improves with data-driven insights. Real-world evidence generation strengthens, providing crucial feedback. The Agent OS accelerates the pace of scientific discovery.
The $18 million in new capital accelerates Manifold's strategic objectives. A primary focus is expanding the "Agent OS." This will unlock more advanced AI capabilities. It enables deeper platform integration across various scientific disciplines. Collaboration infrastructure will also deepen significantly. Research teams will share analyses more effectively. Context reuse will become frictionless across projects. Data sovereignty remains paramount throughout. The entire data ecosystem will scale. Dataset creation simplifies greatly for all users. Organizations participate without relinquishing their data ownership. This fosters a powerful, secure collaborative environment for breakthrough science.
Drug discovery is a lengthy, resource-intensive marathon. Target identification often proves slow and arduous. Manifold's AI dramatically streamlines this process. It rapidly sifts through immense, complex datasets. Promising therapeutic targets emerge faster than ever before. This accelerates preclinical research significantly. Clinical development phases also benefit from these advancements. Manifold's sophisticated tools optimize trial design. They improve patient cohort identification with greater precision. This reduces trial duration and associated costs. Life-changing medicines reach patients much sooner.
Precision medicine demands highly tailored approaches. Manifold enables truly personalized treatments. Its platform analyzes individual patient profiles with advanced algorithms. It recommends specific therapeutic pathways based on unique biological markers. Biomarker insights guide critical treatment decisions. This maximizes treatment efficacy for each patient. It simultaneously minimizes potential adverse effects. Manifold is a vital engine for achieving better patient outcomes. It bridges the critical gap between cutting-edge research and individualized clinical care.
Manifold demonstrates strong product-market fit. Its growth reflects powerful, compounding network effects. Specialized AI agents serve diverse scientific workflows. These include precise cohort identification and accurate biomarker discovery. Treatment pathway analysis improves with data-driven insights. Outcomes research gains much-needed clarity. The customer base expands rapidly, a testament to its value. Foundation Medicine utilizes the platform extensively. The University of Virginia leverages its advanced capabilities for research. Strategic partnerships further extend its reach and impact. The Broad Institute, AWS, and Anthropic are key collaborators. Manifold also operates Terra. Terra supports thousands of researchers. Hundreds of global life sciences organizations rely on its robust infrastructure.
Data silos historically impede scientific progress. Research often suffers from fragmented information sources. Manifold tackles this directly and effectively. It creates a unified data environment for diverse information. Secure sharing protocols are deeply embedded within the platform. Multi-entity collaboration flourishes within this secure ecosystem. Yet, robust data governance ensures absolute control for all participants. Researchers access vast amounts of information. They collaborate without compromising data integrity or ownership. This shared, secure infrastructure accelerates innovation across the board.
This funding signifies more than just company growth. It represents a vital investment in global scientific advancement. It pushes the boundaries of biomedical science forward. It promises significant economic gains for the entire sector. Research productivity will soar to new heights. Drug development becomes more cost-effective and efficient. Breakthroughs will accelerate across the pharmaceutical industry. Manifold stands at the forefront of this transformation. Its technology actively shapes the future. It drives the next era of groundbreaking healthcare innovation.
Manifold continues its expansion trajectory. Its technology closes critical gaps in scientific workflows. It empowers scientists and researchers globally. Future therapeutic advancements depend on such powerful tools. The platform evolves constantly. It adapts to emerging scientific needs and challenges. This ensures its lasting relevance and impact. Manifold's vision actively reshapes healthcare delivery. It builds a healthier tomorrow for countless individuals.